United Therapeutics (UTHR) Stock: Buy, Sell, or Hold?
UTHR - United Therapeutics Corp
$541.70
-29.68 (-5.19%)
▼
5d:
+13.93%
30d:
+10.1%
90d:
-1.01%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 1, 2026 at $581.14 · last confirmed Oct 2, 2026
Strength: 6.6/10
Get Alerted When UTHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: UTHR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: UTHR shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$700.33
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$434.85
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UTHR is currently trading at $541.70, which is considered extended relative to its 30-day fair value range of $483.32 to $523.23. The stock's valuation (Forward PE: 18.8) is in line with its historical norms (17.2). At these levels, the market is pricing in 3.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UTHR is in a strong downtrend. Immediate support is located at $468.97, while resistance sits at $585.79. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: UTHR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $644.36 (+19.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UTHR is in a strong downtrend. Immediate support is located at $468.97, while resistance sits at $585.79. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: UTHR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $644.36 (+19.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$483.32 -
$523.23
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.4%
Protect Your Profits
Holding UTHR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading below Wall St target ($644.36)
- NEUTRAL: Market pricing in 3.1% annual earnings growth - fairly valued
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$483.32 -
$523.23
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$468.97
Resistance Level
$585.79
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.81
Wall Street Target
$644.36
(+19.0%)
Revenue Growth (YoY)
-1.9%
Earnings Growth (YoY)
13.4%
Profit Margin
41.6%
Valuation Premium vs History
+3.1% premium
PE vs Historical
18.8 vs 17.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.1%
(market-implied from PE analysis)
1-Year Target
$558.49
(+3%)
2-Year Target
$575.81
(+6%)
3-Year Target
$593.66
(+10%)
3-Yr Target (if PE normalizes)
(PE: 19→17)
PE COMPRESSION
$542.73
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 10.4%)
$790.35
(+46%)
Base:
(SPY PE: 18.8, Growth: 10.4%)
$728.90
(+35%)
Bear:
(PE: 16.0, Growth: 10.4%)
$619.57
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 20.47 | Current EPS (TTM): $27.91
Bull Case
$648.39
(+20%)
Analyst growth 3.2%, PE expands to 22.5
Base Case
$589.45
(+9%)
Market implied 3.2%, PE stable at 20.5
Bear Case
$388.54
(-28%)
Severe decline -20.0%, PE contracts to 17.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 9:06 PM ET
Data refreshes hourly during market hours. Next update: 10:06 PM
Data refreshes hourly during market hours. Next update: 10:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UTHR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Patusky
SELL
2910 shares
2026-04-24
James Edgemond
SELL
9636 shares
2026-04-23
James Edgemond
SELL
364 shares
2026-04-22
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced UTHR Option Strategies
Professional options setups generated by AI based on today's UTHR price and gamma walls.
